Why the study?
Does combined antiarrhythmic therapy and maternal ursodeoxycholic acid improve outcomes in fetal SVT with hydrops and concurrent maternal obstetric cholestasis?
Does combined antiarrhythmic therapy and maternal ursodeoxycholic acid improve outcomes in fetal SVT with hydrops and concurrent maternal obstetric cholestasis?
Concurrent management of maternal obstetric cholestasis with ursodeoxycholic acid may augment the efficacy of antiarrhythmic therapy in refractory fetal SVT with hydrops.
May support adjunctive ursodeoxycholic acid in refractory fetal SVT with hydrops; hypothesis-generating and requires prospective confirmation.
OBJECTIVE: Supraventricular tachycardia (SVT) is the most common form of sustained fetal tachyarrhythmia in pregnancy. The development of hydrops with SVT is associated with significant worsening of prognosis. CASE: We report a case of fetal SVT with hydrops at 28 weeks' gestation that required both transplacental and direct fetal treatment in a woman with concurrent obstetric cholestasis. Antiarrhythmic therapy and control of the maternal liver function and bile acid levels with ursodeoxycholic acid was associated with a fetal response to treatment resulting in a healthy term live birth. CONCLUSION: Fetal SVT and hydrops fetalis are associated with significant perinatal morbidity and mortality. Resistance to intensive antiarrhythmic therapies may be augmented by the myocardial effects of obstetric cholestasis and remains a challenge for management.
No takes yet. Share an insight, caveat, or question.
Shand et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: